Disease · HP_0002783
Recurrent lower respiratory tract infections
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Recurrent lower respiratory tract infections. Diseases, record HP_0002783. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002783
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Recurrent lower respiratory tract infections
- Open Targets ID
- HP_0002783
- Other names
- Chronic lung infections, Lower respiratory tract infections, Recurrent chest infections
- Highest stage of its drugs
- Approval, for 1 of its 23 drugs, from TTD
Source Open Targets
Drugs23
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NIRSEVIMAB | CHEMBL4297575 | Antibody | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| ACETYLCYSTEINE | CHEMBL600 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ACYCLOVIR SODIUM | CHEMBL1200380 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AMIKACIN | CHEMBL177 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RILEMATOVIR | CHEMBL4437054 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AZITHROMYCIN | CHEMBL529 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYDROXYCHLOROQUINE SULFATE | CHEMBL1690 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LOPINAVIR | CHEMBL729 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RITONAVIR | CHEMBL163 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SISUNATOVIR | CHEMBL4297497 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 23
See all 23 drugsTargets6
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CYP3A4 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 2/3 | https://conductscience.org/library/genes/1576 | Drugs and targets |
| CYP3A43 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 2/3 | https://conductscience.org/library/genes/64816 | Drugs and targets |
| CYP3A5 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 2/3 | https://conductscience.org/library/genes/1577 | Drugs and targets |
| CYP3A7 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 2/3 | https://conductscience.org/library/genes/1551 | Drugs and targets |
| TLR7 | Toll-like receptor 7 | 1 | Toll-like receptor 7 antagonist | Phase 2/3 | https://conductscience.org/library/genes/51284 | Drugs and targets |
| TLR9 | Toll-like receptor 9 | 1 | Toll-like receptor 9 antagonist | Phase 2/3 | https://conductscience.org/library/genes/54106 | Drugs and targets |
Trials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01076153 | Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR | 760 | 2011-06-29 | Respiratory Tract Infection | CLARITHROMYCIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01076166 | Recovery Time in Children With Lower Respiratory Tract Infections Treated With Klacid® Granules for Oral Suspension. | 337 | 2011-03-07 | Lower Respiratory Tract Infection | CLARITHROMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01075204 | Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER) | 335 | 2013-01-30 | Respiratory Tract Infection | CLARITHROMYCIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04354428 | Treatment for COVID-19 in High-Risk Adult Outpatients | Phase 2/3 | 289 | 2022-08-08 | COVID-19, SARS-CoV-2 | AZITHROMYCIN, HYDROXYCHLOROQUINE SULFATE, LOPINAVIR, RITONAVIR | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04225897 | A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection. | Phase 2 | 51 | 2024-10-23 | Respiratory Syncytial Virus (RSV), Lower Resp Tract Infection | SISUNATOVIR | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01952470 | Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant. | Phase 2 | 32 | 2019-08-28 | Lung Transplant Infection, Lower Respiratory Tract Infection | DORNASE ALFA, SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04583280 | A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) | Phase 3 | 28 | 2023-04-10 | Respiratory Tract Infections | RILEMATOVIR | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT06102174 | A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV | Phase 1 | 10 | 2025-12-30 | Respiratory Syncytial Virus Infections | SISUNATOVIR | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04639817 | Trimethoprim-Sulfamethoxazole vs Levofloxacin as Targeted Therapy for Stenotrophomonas Maltophilia Infections: a Retrospective Cohort Study | 1,621 | Stenotrophomonas Infection | LEVOFLOXACIN, TRIMETHOPRIM | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT04196608 | In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients | 1,005 | Ceftolozane/Tazobactam, Imipenem/Relebactam, Hematology and Oncology | CEFTOLOZANE, IMIPENEM, RELEBACTAM, TAZOBACTAM | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dornase Alfa vs Isotonic Saline: deaths from any cause | 1 of 16 | 1 of 16 | 32 | NCT01952470 | Trial comparisons |
| Dornase Alfa vs Isotonic Saline: serious adverse events | 0 of 16 | 0 of 16 | 32 | NCT01952470 | Trial comparisons |
| Rilematovir vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 11 of 20 | 5 of 8 | 28 | NCT04583280 | Trial comparisons |
| Rilematovir vs Placebo: deaths from any cause | 0 of 20 | 0 of 8 | 28 | NCT04583280 | Trial comparisons |
| Rilematovir vs Placebo: serious adverse events | 1 of 20 | 0 of 8 | 28 | NCT04583280 | Trial comparisons |
| Rilematovir vs Placebo: Number of Participants With Post-baseline RSV-related Complications | 3 of 19 | 1 of 8 | 27 | NCT04583280 | Trial comparisons |
| Rilematovir vs Placebo: Number of Participants With Medical Encounters and Treatments | 3 of 19 | 1 of 8 | 27 | NCT04583280 | Trial comparisons |
Papers from its trials27
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002783
GET https://conductscience.org/api/diseases/v1/HP_0002783/drugs?page=2